BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16317729)

  • 1. Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin.
    Ayas M; Al-Musa A; Al-Jefri A; Al-Seraihi A; Al-Mahr M; Rifai S; El-Solh H
    Pediatr Blood Cancer; 2007 Jul; 49(1):103-4. PubMed ID: 16317729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita.
    Dror Y; Freedman MH; Leaker M; Verbeek J; Armstrong CA; Saunders FE; Doyle JJ
    Bone Marrow Transplant; 2003 May; 31(10):847-50. PubMed ID: 12748659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
    Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
    Kröger N; Zabelina T; Binder T; Ayuk F; Bacher U; Amtsfeld G; Lellek H; Schrum J; Erttmann R; Eiermann T; Zander A
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):454-62. PubMed ID: 19285633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
    Maschan AA; Trakhtman PE; Balashov DN; Shipicina IP; Skorobogatova EV; Skvortsova YV; Dyshlevaja ZM; Samochatova EV; Rumiantsev AG
    Bone Marrow Transplant; 2004 Aug; 34(4):305-7. PubMed ID: 15195080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
    Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
    Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
    Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation from related and unrelated donors for aplastic anaemia in adults--a single-centre experience.
    Buchholz S; Dammann E; Koenecke Ch; Stadler M; Franzke A; Blasczyk R; Bremer M; Krauter J; Hertenstein B; Ganser A; Eder M
    Ann Hematol; 2008 Jul; 87(7):551-6. PubMed ID: 18386010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan.
    Kobayashi R; Ariga T; Nonoyama S; Kanegane H; Tsuchiya S; Morio T; Yabe H; Nagatoshi Y; Kawa K; Tabuchi K; Tsuchida M; Miyawaki T; Kato S
    Br J Haematol; 2006 Nov; 135(3):362-6. PubMed ID: 17032176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Unrelated bone marrow transplantation in two severe aplastic anemia patients preconditioned with a regimen of cyclophosphamide, antithymocyte globulin, and total body irradiation].
    Mizue N; Watanabe J; Katoh S; Oda T; Suzuki N; Kudoh T
    Rinsho Ketsueki; 1999 Mar; 40(3):213-7. PubMed ID: 10222628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
    Resnick IB; Aker M; Tsirigotis P; Shapira MY; Abdul-Hai A; Bitan M; Gesundheit B; Amar A; Ackerstein A; Samuel S; Slavin S; Or R
    Bone Marrow Transplant; 2007 Nov; 40(10):957-64. PubMed ID: 17846604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matched-related allogeneic stem cell transplantation in Saudi patients with Fanconi anemia: 10 year's experience.
    Ayas M; Al-Jefri A; Al-Seraihi A; Elkum N; Al-Mahr M; El-Solh H
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S45-S48. PubMed ID: 18724300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.
    Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A
    Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin.
    Sedlácek P; Formánková R; Keslová P; Srámková L; Hubácek P; Król L; Kulich M; Starý J
    Bone Marrow Transplant; 2006 Dec; 38(11):745-50. PubMed ID: 17041606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
    Kumar R; Prem S; Mahapatra M; Seth T; Chowdhary DR; Mishra P; Pillai L; Narendra AM; Mehra NK; Saxena R; Choudhry VP
    Bone Marrow Transplant; 2006 Apr; 37(8):745-9. PubMed ID: 16518427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
    George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
    Bone Marrow Transplant; 2007 Jul; 40(1):13-8. PubMed ID: 17450183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.